. 2019 Jun 14;21:148. doi: 10.1186/s13075-019-1932-9

Table 3.

Secondary outcome measures

All patients (n = 63)	Baseline (B_vs)	Vibrotac. S. (VS)	Baseline (B_sham)	Sham	(B_vs − VS) > (B_sham − Sham)
Unrefreshed Sleep	69.6 ± 17.8	55.1 ± 22.5	67.1 ± 18.5	60.3 ± 23.4	t = 2.2 p = 0.033
Daily Activity Impact	70.6 ± 17.9	67.9 ± 16.9	69.7 ± 17.8	69.8 ± 18.6	t = 1.7 p = 0.098
Anxiety (HADS)	10.9 ± 4.4	10.1 ± 3.9	11.0 ± 3.9	10.9 ± 4.3	t = 1.4 p = 0.164
Depression (HADS)	9.3 ± 4.7	9.3 ± 4.7	9.3 ± 4.4	9.3 ± 4.6	t = − 0.6 p = 0.955
FIQ	61.9 ± 16.2	54.8 ± 17.3	60.7 ± 17.9	58.1 ± 18.0	t = 1.9 p = 0.069
Vibrotactile S. first (n = 33)	Baseline (B₁)	Vibrotac. S. (VS)	Baseline (B₂)	Sham	(B₁ − VS) > (B₂ − Sham)
Unrefreshed Sleep	70.8 ± 16.8	52.7 ± 23.8	61.9 ± 20.6	61.9 ± 24.2	t = 4.4 p = 0.0001
Daily Activity Impact	68.9 ± 19.4	64.8 ± 18.6	66.6 ± 19.0	67.7 ± 20.3	t = 2.4 p = 0.020
Anxiety (HADS)	10.7 ± 4.7	10.0 ± 3.8	10.5 ± 4.2	10.7 ± 4.4	t = 1.1 p = 0.261
Depression (HADS)	9.8 ± 4.8	9.4 ± 4.5	9.0 ± 4.8	9.6 ± 4.7	t = 1.5 p = 0.148
FIQ	63.1 ± 14.0	54.1 ± 18.2	57.5 ± 19.0	58.3 ± 18.7	t = 3.4 p = 0.002
Sham first (n = 30)	Baseline (B₁)	Sham	Baseline (B₂)	Vibrotac. S. (VS)	(B₂ − VS) > (B₁ − Sham)
Unrefreshed Sleep	72.8 ± 14.1	58.6 ± 22.7	68.4 ± 19.1	57.6 ± 21.0	t = − 0.6 p = 0.527
Daily Activity Impact	73.2 ± 15.9	71.1 ± 16.7	72.4 ± 16.2	71.3 ± 14.3	t = − 0.7 p = 0.502
Anxiety (HADS)	11.6 ± 3.4	11.2 ± 4.2	11.2 ± 4.2	10.2 ± 4.0	t = 0.8 p = 0.427
Depression (HADS)	9.8 ± 3.9	8.9 ± 4.6	8.8 ± 4.6	9.1 ± 4.9	t = − 1.4 p = 0.171
FIQ	64.2 ± 16.3	57.8 ± 17.5	60.7 ± 18.4	55.6 ± 16.5	t = − 0.4 p = 0.753
	(B₁ − VS) > (B₁ − Sham)		(B₂ − VS) > (B₂ − Sham)
Unrefreshed Sleep	t = 1.0 p = 0.336		t = 2.2 p = 0.029
Daily Activity Impact	t = 1.4 p = 0.162		t = 1.3 p = 0.198
Anxiety (HADS)	t = 0.3 p = 0.759		t = 1.8 p = 0.082
Depression (HADS)	t = −0.6 p = 0.549		t = 0.5 p = 0.595
FIQ	t = 0.7 p = 0.462		t = 1.6 p = 0.111

FIQ Fibromyalgia Impact Questionnaire, HADS Hospital Anxiety and Depression Scale